HIT Consultant November 11, 2024
Fred Pennic

What You Should Know:

Oxford Cannabinoid Technologies (OCT) has announced a significant milestone in its drug discovery program: the successful “proof of concept” of its AI-enabled drug discovery asset.

– Developed in collaboration with New York-based tech consultancy Hypatia AI, this cutting-edge tool promises to accelerate OCT’s research and development of non-addictive pain medications.

Accelerating Drug Discovery with AI

Hypatia AI’s technology acts as an “endlessly resourceful research assistant,” leveraging large language models to analyze vast amounts of scientific literature and uncover hidden connections. This targeted approach allows OCT’s scientific team to:

  • Enhance Efficiency: Spend less time searching for information and more time focused on discovery.
  • Gain Deeper Insights: Uncover relationships and insights that may be...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Pharma, Pharma / Biotech, Technology
10 signs AI is ‘eating the world (of venture capital)’
2024: record year for AI trials
2025: Provider organizations will embrace new AI and analytics techniques
AI and Automation in Healthcare – 2025 Health IT Predictions
Why The Public And Private Sectors Must Jointly Define Responsible AI

Share This Article